Reference health

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population

https://doi.org/10.7326/m18-2753
CiteStamped reference-health badge
1 of 42 checkable references need attention · checked 2026-07-24

At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.

References needing attention

does not resolve to a known work10.2307/2670170
The 41 checked references that resolve
resolves10.1002/ijc.29210
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
resolves10.1053/j.gastro.2011.12.061
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
resolves10.1002/cncr.29936
Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer
resolves10.1002/hep.28156
AASLD guidelines for treatment of chronic hepatitis B
resolves10.1053/j.gastro.2012.10.005
Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis
resolves10.1016/j.cgh.2017.04.039
Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis
resolves10.1371/journal.pone.0028813
Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites
resolves10.1002/hep.28506
Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES
resolves10.1007/s10654-013-9806-y
Statin use and risk of hepatocellular carcinoma
resolves10.1093/jnci/djv009
Statin Use and Risk of Primary Liver Cancer in the Clinical Practice Research Datalink
resolves10.1200/JCO.2011.36.0917
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
resolves10.1038/ajg.2010.475
Statin Use and the Risk of Liver Cancer: A Population-Based Case–Control Study
resolves10.1016/j.canep.2014.06.009
Statin use and risk of hepatocellular carcinoma in a U.S. population
resolves10.1002/pds.1870
Pravastatin use and cancer risk: a meta‐analysis of individual patient data from long‐term prospective controlled trials in Japan
resolves10.1111/bcpt.12844
Statins and Angiotensin‐Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease
resolves10.1111/j.1365-2893.2008.00982.x
<b>Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community‐based register study</b>
resolves10.1186/1471-2458-11-450
External review and validation of the Swedish national inpatient register
resolves10.1093/aje/kwg231
Evaluating Medication Effects Outside of Clinical Trials: New-User Designs
resolves10.1053/j.gastro.2015.10.007
Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C–Related Compensated Cirrhosis
resolves10.2147/CLEP.S78145
Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study
resolves10.1002/pds.4231
Has cost inhibited the uptake of more potent statins in England?
resolves10.1186/s12888-014-0348-y
Statin use and risk of depression: a Swedish national cohort study
resolves10.1002/pds.1294
The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months
resolves10.1080/02841860802247664
The completeness of the Swedish Cancer Register – a sample survey for year 1998
resolves10.1080/00273171.2011.568786
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
resolves10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group
resolves10.1016/j.jclinepi.2009.03.012
Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes
resolves10.1371/journal.pmed.1002007
Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study
resolves10.1053/j.gastro.2019.01.026
Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis
resolves10.1016/j.tem.2009.07.005
Hepatitis C virus hijacks host lipid metabolism
resolves10.1073/pnas.0409834102
Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids
resolves10.1128/JVI.05423-11
Cholesterol Depletion of Hepatoma Cells Impairs Hepatitis B Virus Envelopment by Altering the Topology of the Large Envelope Protein
resolves10.1016/j.cell.2018.08.070
The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery
resolves10.1016/j.antiviral.2010.02.325
Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro
resolves10.1111/j.1582-4934.2009.00771.x
Lipophilic but not hydrophilic statins selectively induce cell death in gynecological cancers expressing high levels of HMGCoA reductase.
resolves10.1016/j.xphs.2017.04.053
Effect of Liver Disease on Hepatic Transporter Expression and Function
resolves10.1016/j.cancergen.2015.03.008
Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells
resolves10.1016/j.jhep.2005.04.010
Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor
resolves10.3892/ijo.2011.1273
Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression
resolves10.1016/j.jclinepi.2003.12.008
Time-dependent bias was common in survival analyses published in leading clinical journals
resolves10.1161/CIRCULATIONAHA.115.019014
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.7326/m18-2753"><img src="https://citestamp.com/citestamped/10.7326/m18-2753/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.7326/m18-2753/badge.svg)](https://citestamp.com/citestamped/10.7326/m18-2753)